Servier, MacroGenics Forge Option Deal For Cancer Drug
This article was originally published in The Pink Sheet Daily
The French pharma acquires the right to license the antibody MGA271, which has received strong interest since BMS’s Yervoy was approved in March.
You may also be interested in...
The French pharma paid $20 million up-front for rights to option three preclinical programs, including drugs targeting both solid and liquid-tumor cancers.
With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.
The startup strikes a two-drug oncology deal with Pfizer and a ten-target agreement with BI just days after Lilly halted development of its lead compound.